Summary:
Clinical Research Study for Individuals with Parkinson’s Disease
We are conducting a double-blind, randomized, placebo-controlled, multicenter clinical study to evaluate the efficacy and safety of NE3107 in adults diagnosed with Parkinson’s disease (PD) who are treatment-naïve and in need of therapy for motor symptoms.
Study Overview:
Participants will take part in a study that includes:
-
Screening and Clinical Stability Assessment (approximately 4–6 weeks)
-
Double-Blind Treatment Period (12 weeks, NE3107 or placebo, twice daily)
-
Safety Follow-up (4 weeks post-treatment)
During the study, eligible participants will receive investigational product capsules and undergo scheduled clinical evaluations, both in-person and virtual, to monitor safety and symptom progression.
Key Eligibility:
Adults diagnosed with Parkinson’s disease
* Male/Female ages 45-80 years old
Have not yet started PD treatment but are in need of therapy
Willing to defer other PD treatments during the study period
Qualified participants will contribute to advancing research on a potential new therapy for Parkinson’s disease.
Qualified Participants May Receive:
Participant who qualify may receive:
- Study Related Exams, EKG & Lab Work at No Cost
- Complimentary Transportation
- No Insurance Necessary
- compensation for time and travel
- Free medication